BIONTECH Says Gotistobart Nearly Doubled Survival in Lung Cancer Trial

BioNTech and partner OncoC4 report first median overall survival data from stage 1 of the Phase 3 PRESERVE-003 trial in squamous NSCLC.

Share
Gotistobart is being developed for patients with squamous non-small cell lung cancer.
Source: Wikimedia